It seems there are a few reasons one can imagine why we're doing this review. One of them is to improve the act. Another is to kick-start government, so that they actually follow through on some of the things that are based on this act. And then there's the public aspect: the public information, public pressure.
It seems the body testing.... Because the NPRI and other listing mechanisms with respect to the public in particular are an abstract thing--there's a list that happens--you folks or other people try to draw attention to what's going on, but it doesn't mean much. Building this into our review and study, in terms of the effectiveness of what the U.S. or the Europeans have been able to do regarding the development of better and more effective law, seems important.
I'm wondering if I could move to industry for a moment, because I imagine we'll be having a panel from industry as well. They often cite confidentiality, competitiveness, and other factors as barriers to potentially listing or doing something about restricting a chemical. In the terms of the scope of this study, is there anything either of you would suggest in the way we approach the industrial side of how CEPA is used and applied, or not applied, that would make sense?